Evidence map›Paper›PMID 31067539›Full record

ArticleDigestion2020

Efficacy of Endoscopic Evaluation of Acute Radiation Esophagitis during Chemoradiotherapy with Proton Beam Therapy Boost for Esophageal Cancer.

Kenkei Hasatani, Hiroyasu Tamamura, Kazutaka Yamamoto, Hiroyuki Aoyagi, Tamon Miyanaga, Yasuharu Kaizaki, Takeshi Sawada

Open access · hybridAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestion, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kenkei HasataniDepartment of Gastroenterology, Fukui Prefectural Hospital, Fukui, Japan.
Hiroyasu TamamuraProton Therapy Center, Fukui Prefectural Hospital, Fukui, Japan.
Kazutaka YamamotoProton Therapy Center, Fukui Prefectural Hospital, Fukui, Japan.
Hiroyuki AoyagiDepartment of Gastroenterology, Fukui Prefectural Hospital, Fukui, Japan.
Tamon MiyanagaDepartment of Surgery, Fukui Prefectural Hospital, Fukui, Japan.
Yasuharu KaizakiDepartment of Pathology, Fukui Prefectural Hospital, Fukui, Japan.
Takeshi SawadaDivision of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan, takeshisawada@icloud.com.
Fukui Prefectural Hospital · JPKanazawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo evaluate the utility of endoscopy for assessing radiation esophagitis during chemoradiotherapy (CRT) with proton beam therapy (PBT) boost for esophageal cancer.

methodsBetween December 2012 and December 2016, 38 patients with esophageal cancer were treated with CRT with PBT boost. To evaluate radiation esophagitis, endoscopy was performed after administration of CRT with standard PBT boost (total dose 50-60 Gy relative biological effectiveness [RBE]). Radiation esophagitis was evaluated and classified into 5 newly developed endoscopic grades (Fukui Acute Radiation Esophagitis [FARE] grade). The additional PBT boost was then adjusted and delivered (2-20 Gy [RBE]) to a maximum total dose of 74.4 Gy (RBE) based on the degree of radiation esophagitis, probability of residual tumor, and patient's general condition. To evaluate the utility of endoscopic examination, the incidences of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 4.0) were determined at the time of endoscopic examination after CRT with standard PBT boost (50-60 Gy [RBE]) and at the completion of treatment (60-74.4 Gy [RBE]), as well as during the 90 days from the beginning of treatment.

resultsThere was a significant correlation between FARE grade and CTCAE esophagitis grade (ρ = 0.48; p = 0.03). Moreover, endoscopy detected severe esophagitis in an asymptomatic patient. Radiation dose escalation was achieved without severe acute adverse events. There was no significant difference between the incidence of acute toxicity at the time of the CRT with standard PBT boost (50-60 Gy [RBE]) and the higher dose at the completion of treatment (60-74.4 Gy [RBE]), which suggests this dose escalation strategy is safe.

conclusionEndoscopic evaluation of radiation esophagitis using FARE grades was safely performed and useful for adjusting added radiation to ensure the safety of escalations in CRT with PBT boost for esophageal cancer.

Indexed as

Acute DiseaseAgedAged, 80 and overChemoradiotherapyClinical Decision-MakingEndoscopyEsophageal NeoplasmsEsophagitisFemaleHumansMaleMiddle AgedProton TherapyRadiation InjuriesRadiation MonitoringRelative Biological EffectivenessEndoscopic gradeEsophageal cancerProton beam therapyRadiation esophagitis

Identifiers

PMID31067539
PMCPMC7384344
OpenAlexW2944339156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.